(LMAT) LeMaitre Vascular - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5255582018

Stock: Allografts, Catheters, Biologic, Grafts, Valvulotomes

Total Rating 30

Risk 94

Buy Signal -1.32

Medical Instruments & Supplies » Health Care Equipment
Age: 19.3y

Market Cap: 1,928m
Avg Trading Vol: 10.7M USD

ATR: 2.75%
Peers RS (IBD): 46.43

EPS (Earnings per Share)

EPS CAGR: -43.12%
EPS Trend: 43.1%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 12.31%
Rev. Trend: 96.6%

Last SUE: -1.10
Qual. Beats: 0

Dividends

Dividend Yield	0.94%
Yield on Cost 5y	1.74%
Yield CAGR 5y	16.12%
Payout Consistency	100.0%
Payout Ratio	47.1%

Risk 5d forecast
Volatility	32.4%
Relative Tail Risk	-6.16%

Reward TTM
Sharpe Ratio	-0.34
Alpha	-22.21

Character TTM
Beta	0.664
Beta Downside	0.719

Drawdowns 3y
Max DD	33.32%
CAGR/Max DD	0.69

Description: LMAT LeMaitre Vascular January 14, 2026

LeMaitre Vascular Inc. (NASDAQ: LMAT) designs, manufactures, and sells a broad portfolio of vascular-surgery devices-including allograft tissue grafts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, biosynthetic grafts, and specialty closure systems-across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company reaches customers via a direct sales force and a network of distributors, and it also offers cryopreservation services for human cadaver tissue.

Key recent metrics: FY 2023 revenue reached approximately $210 million, up ~12% year-over-year, with an operating margin near 15% and R&D spending representing about 8% of sales. The vascular-device market is being propelled by an aging population, rising prevalence of peripheral artery disease, and a sustained shift toward minimally invasive, biologic-graft-based procedures, which together support a 5%-6% CAGR in U.S. healthcare spending on vascular therapies.

For a deeper, data-driven look at LMAT’s valuation and peer landscape, you might explore the analytical tools available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income: 53.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.19 > 1.0
NWC/Revenue: 173.8% < 20% (prev 92.84%; Δ 81.01% < -1%)
CFO/TA 0.12 > 3% & CFO 73.3m > Net Income 53.3m
Net Debt (160.1m) to EBITDA (86.7m): 1.85 < 3
Current Ratio: 13.58 > 1.5 & < 3
Outstanding Shares: last quarter (24.4m) vs 12m ago 6.81% < -2%
Gross Margin: 70.97% > 18% (prev 0.68%; Δ 7029 % > 0.5%)
Asset Turnover: 49.40% > 50% (prev 56.50%; Δ -7.10% > 0%)
Interest Coverage Ratio: 18.69 > 6 (EBITDA TTM 86.7m / Interest Expense TTM 4.09m)

Altman Z'' 7.41

A: 0.70 (Total Current Assets 452.0m - Total Current Liabilities 33.3m) / Total Assets 598.1m
B: 0.29 (Retained Earnings 173.7m / Total Assets 598.1m)
C: 0.16 (EBIT TTM 76.4m / Avg Total Assets 487.5m)
D: 0.78 (Book Value of Equity 171.0m / Total Liabilities 219.1m)
Altman-Z'' Score: 7.41 = AAA

Beneish M -3.33

DSRI: 0.89 (Receivables 32.4m/32.3m, Revenue 240.9m/213.0m)
GMI: 0.96 (GM 70.97% / 68.34%)
AQI: 0.60 (AQ_t 0.17 / AQ_t-1 0.29)
SGI: 1.13 (Revenue 240.9m / 213.0m)
TATA: -0.03 (NI 53.3m - CFO 73.3m) / TA 598.1m)
Beneish M-Score: -3.33 (Cap -4..+1) = AA

What is the price of LMAT shares?

As of February 07, 2026, the stock is trading at USD 87.42 with a total of 129,975 shares traded.
Over the past week, the price has changed by +2.88%, over one month by +4.68%, over three months by +2.36% and over the past year by -11.62%.

Is LMAT a buy, sell or hold?

LeMaitre Vascular has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold LMAT.

StrongBuy: 3
Buy: 2
Hold: 6
Sell: 0
StrongSell: 0

What are the forecasts/targets for the LMAT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	103.7	18.6%
Analysts Target Price	103.7	18.6%
ValueRay Target Price	101.2	15.8%

LMAT Fundamental Data Overview February 03, 2026

P/E Trailing = 36.625
P/E Forward = 32.1543
P/S = 8.0029
P/B = 5.0871
P/EG = 1.8392
Revenue TTM = 240.9m USD
EBIT TTM = 76.4m USD
EBITDA TTM = 86.7m USD
Long Term Debt = 168.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.79m USD (from shortTermDebt, last quarter)
Debt = 185.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 160.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.77b USD (1.93b + Debt 185.6m - CCE 343.1m)
Interest Coverage Ratio = 18.69 (Ebit TTM 76.4m / Interest Expense TTM 4.09m)
EV/FCF = 26.73x (Enterprise Value 1.77b / FCF TTM 66.2m)
FCF Yield = 3.74% (FCF TTM 66.2m / Enterprise Value 1.77b)
FCF Margin = 27.49% (FCF TTM 66.2m / Revenue TTM 240.9m)
Net Margin = 22.14% (Net Income TTM 53.3m / Revenue TTM 240.9m)
Gross Margin = 70.97% ((Revenue TTM 240.9m - Cost of Revenue TTM 69.9m) / Revenue TTM)
Gross Margin QoQ = 75.28% (prev 70.02%)
Tobins Q-Ratio = 2.96 (Enterprise Value 1.77b / Total Assets 598.1m)
Interest Expense / Debt = 0.70% (Interest Expense 1.30m / Debt 185.6m)
Taxrate = 23.09% (5.21m / 22.6m)
NOPAT = 58.8m (EBIT 76.4m * (1 - 23.09%))
Current Ratio = 13.58 (Total Current Assets 452.0m / Total Current Liabilities 33.3m)
Debt / Equity = 0.49 (Debt 185.6m / totalStockholderEquity, last quarter 378.9m)
Debt / EBITDA = 1.85 (Net Debt 160.1m / EBITDA 86.7m)
Debt / FCF = 2.42 (Net Debt 160.1m / FCF TTM 66.2m)
Total Stockholder Equity = 356.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.94% (Net Income 53.3m / Total Assets 598.1m)
RoE = 14.96% (Net Income TTM 53.3m / Total Stockholder Equity 356.6m)
RoCE = 14.56% (EBIT 76.4m / Capital Employed (Equity 356.6m + L.T.Debt 168.4m))
RoIC = 11.21% (NOPAT 58.8m / Invested Capital 524.7m)
WACC = 7.67% (E(1.93b)/V(2.11b) * Re(8.36%) + D(185.6m)/V(2.11b) * Rd(0.70%) * (1-Tc(0.23)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.21%
[DCF Debug] Terminal Value 82.33% ; FCFF base≈53.1m ; Y1≈65.5m ; Y5≈111.6m
Fair Price DCF = 81.97 (EV 2.02b - Net Debt 160.1m = Equity 1.86b / Shares 22.7m; r=7.67% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 43.06 | EPS CAGR: -43.12% | SUE: -4.0 | # QB: 0
Revenue Correlation: 96.57 | Revenue CAGR: 12.31% | SUE: -1.10 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.62 | Chg30d=+0.031 | Revisions Net=+3 | Analysts=9
EPS next Year (2026-12-31): EPS=2.59 | Chg30d=+0.099 | Revisions Net=+4 | Growth EPS=+7.0% | Growth Revenue=+9.1%

Additional Sources for LMAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle